Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab

BACKGROUND: The standard treatment for patients with unresectable locally advanced (LA) non‐small cell lung cancer (NSCLC) is chemoradiotherapy (CRT). Consolidation therapy with durvalumab after CRT demonstrated survival benefits and was approved in Japan in July 2018. The use of immune checkpoint i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Fukui, Tomoya, Hosotani, Shinji, Soda, Itaru, Ozawa, Takahiro, Kusuhara, Seiichiro, Kakegawa, Mikiko I., Kasajima, Masashi, Hiyoshi, Yasuhiro, Igawa, Satoshi, Yokoba, Masanori, Mitsufuji, Hisashi, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Ishiyama, Hiromichi, Naoki, Katsuhiko
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7113036/
https://ncbi.nlm.nih.gov/pubmed/32057187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13357
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados